Condition
Sarcomatoid Mesothelioma
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
300%
3 of 1 completed with results
Key Signals
3 with results50% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed1
Terminated1
Active Not Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT01064648Phase 1Active Not Recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
NCT02399371Phase 2Completed
Pembrolizumab in Treating Patients With Malignant Mesothelioma
NCT01861301Phase 2Terminated
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Showing all 3 trials